Former Shire CEO shakes up Galderma as IPO decision looms

Flemming Ørnskov is "doubling down on science" and readying Galderma, formerly owned by Nestle, for competition with the likes of Sanofi.
Photo: Shire/ PR
Photo: Shire/ PR
by James Paton, bloomberg

Flemming Ørnskov led Shire's expansion into rare diseases before the drugmaker's USD 62bn (DKK 399.3bn) sale to Takeda Pharmaceutical Co. in 2019. Now he's plotting a new course for a skincare business that Nestle SA gave up on.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading